Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma

LIJUAN HAN1, FEIFEI LIU2, RUPING LI1, ZHAOMING LI1, XINFENG CHEN3, ZHIYUAN ZHOU1, XUDONG ZHANG1, TENGPENG HU1, YI ZHANG3, KEN YOUNG4, SUKE SUN5, JIANGUO WEN5 and MINGZHI ZHANG1

1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000; 2Department of Sports Medicine, Research Center of Sports Medicine, Xiangya Hospital of Central South University, Changsha, Hunan 410008; 3Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China; 4Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230-1439, USA; 5Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China

Received September 21, 2013; Accepted April 3, 2014

Abstract. Extranodal natural killer/T-cell lymphoma (ENKL) is marked by a profound cellular immune deficiency that may influence the capacity of T cells to extract an efficient antitumor immune response. It has been confirmed that the B7-CD28 pathway may promote tumor immune evasion by providing a negative regulatory signal. The current study analyzed the expression of programmed death 1 (PD-1)/programmed death ligand (PD-L) in ENKL cell lines and tissues. The functional studies were performed to analyze the functional activity of PD-L1 interacting with effective T cells in ENKL. PD-L1 and PD-L2 mRNA levels in ENKL cell lines were markedly upregulated compared with those in normal natural killer cells. The proteins constitutively expressed in the 30 ENKL specimens were significantly higher than in the 20 rhinitis specimens. In addition, PD-L1 and PD-L2 expression were found to closely correlate with certain clinical histopathological parameters. Furthermore, the count of PD-1+ tumor-infiltrating T lymphocytes was found to negatively correlate with the expression of PD-L1 and PD-L2. The PD-1 expression in the CD4+ and CD8+ T-cell subsets of 20 ENKL patients prior to therapy were significantly higher than that of the 10 healthy volunteers. In the functional studies, the cytokines (interleukin-2 and interferon-γ) secreted by CD8+ T cells were inhibited by PD-L1 expression in SNK-6 cells and this was restored with the presence of the PD-L1 blocking antibody. However no direct effect of PD-L1 was identified on CD8+ T-cell apoptosis and CD8+ T-cell cytotoxicity, as assessed by the proliferation of SNK-6 cells in the presence or absence of the neutralizing anti-PD-L1 antibody. The results of the current study revealed that PD-Ls and PD-1 are aberrantly expressed in ENKL and, furthermore, PD-L1 expression in SNK-6 cells was found to inhibit the activity of CD8+ T-cell cytokine secretion. This indicated that the PD-Ls may prevent effective antitumor immunity in vivo by interacting with tumor T cells, which provides important evidence to delineate the cellular immune deficiency mechanism in ENKL. Therefore, PD-1/PD-Ls are predicted to become novel targets for ENKL immunotherapy.

Introduction

Extranodal natural killer/T-cell lymphoma (ENKL) is a rare subtype of non-Hodgkin lymphoma (NHL) and is characterized by distinct morphology, immunophenotype and biological behavior (1). According to the current World Health Organization (WHO) classification, extranodal natural killer/T-cell lymphoma is divided into ENKL and the aggressive natural killer cell leukemia (ANKL) (2). The tumor cells of ENKL derived from natural killer (NK) cells and, more rarely, T cells closely correlate with Epstein-Barr virus (EBV) infection (2,3). In addition, ENKL is estimated to account for 3-8% of malignant lymphomas in China and the incidence is much higher than that in Western countries (4). According to the original location, ENKL can be divided into two major subtypes; nasal and extranasal diseases. The nasal and paranasal lesions, including the upper aerodigestive tract, account for ≤80% of ENKLs (5). Currently, immunosuppression or immune disorders frequently occur in ENKL patients and ENKL is recognized as a highly aggressive neoplasm with poor therapeutic effects and prognosis. Thus, no uniform treatment regimen for ENKL has been determined (5), and the causes of the condition require investigation. We hypothesize that the inhibitory signals expressed in tumor cells inhibit the effective T-cell immune response, which aids the tumor cells
to evade and destruct the immune surveillance and, ultimately, promote the pathogenesis and progression of ENKL.

The identification of the costimulatory molecules of the B7-CD28 superfamily has led to tremendous advancements in understanding the mechanism of T-cell immunity in numerous tumors. The programmed death ligand (PD-L) 1 and PD-L2 are two ligands of programmed death 1 (PD-1) and are members of the B7 immunoglobulin superfamily. PD-1, an immune inhibitory receptor, is a member of the CD28 family and, as a negative regulator, inhibits T-cell activity by conjunction with signaling through the T-cell receptor (6). In previous studies, the PD-1-PD-L signaling system has been demonstrated to be pivotal in immune tolerance, autoimmune diseases, chronic infections and inflammatory diseases, and has demonstrated a negative role in regulating the immune response (7,8). Notably, the PD-1/PD-L pathway is involved in tumor immune evasion of cancers, including melanoma, lung, esophageal, breast, renal and ovarian cancers, as well as hematopoietic malignancies (9). Iwamura et al (10) demonstrated that the small interfering RNA-mediated knockdown of PD-L1 or PD-L2 may enhance tumor-specific human T-cell effector functions, such as interferon (IFN)-γ production and antigen-specific cytotoxicity. However, a series of clinical trials concerning the systemic administration of therapeutic antibodies for blocking PD-1 or PD-L1 have shown a promising clinical effect in several solid tumors (11,12). PD-L1 and PD-L2 have an extensive expression pattern in NHL, including T- and B-cell lymphoma (13); however, the expression has not yet been characterized in ENKL. The current study addressed the role of the PD-Ls, particularly PD-L1, in effective T-cell interactions in ENKL. The results are likely to provide important evidence to delineate the cellular immune deficiency mechanism in ENKL and a potential strategy for immunotherapy against ENKL.

Materials and methods

Cell lines and peripheral blood mononuclear cell (PBMC) separation. The human ENKL SNK-6 and YTS cell lines were used. The SNK-6 cell line was a gift from Professor Norio Shimizu (Chiba University, Chiba, Japan) and the cells were cultured in RPMI-1640 (Beijing Solarbio Science and Technology Co., Ltd., Beijing, China) medium containing 2 mmol/l glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin, supplemented with 1,000 U/ml interleukin (IL)-2 (Beijing SL Pharmaceutical Co., Ltd., Beijing, China) and 10% human AB serum provided by the Blood Center of Henan Province (Zhengzhou, China). The YTS cell line was a gift from Professor Scott Kaufmann (Mayo Medical Center, Rochester, MN, USA) and the cells were cultured in RPMI-1640, supplemented with 1% non-essential amino acids and 10% fetal calf serum (FCS; Hangzhou Sijiqing Biological Engineering Materials Co., Ltd., Hangzhou, China). The following cell lines were stored in a liquid nitrogen container at the Institute of Clinical Medicine of the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) and cultured in RPMI-1640 supplemented with 10% FCS: Human acute T-lymphoblastic leukemia Jurkat cell line (Shanghai Institute of Cellular Biology of Chinese Academy of Science, Shanghai, China); human cutaneous T-cell lymphoma Hut-78 cell line (gift from Professor Scott Kaufmann; Mayo Medical Center); anaplastic large cell lymphoma (ALCL) Karpas-299 cell line (Shanghai Institute of Cellular Biology of Chinese Academy of Science); diffuse large B-cell lymphoma LY-1 and LY-8 cell lines (Shanghai Institute of Cellular Biology of Chinese Academy of Science); and Burkitt lymphoma Raji and Ramos cell lines (Shanghai Institute of Cellular Biology of Chinese Academy of Science). All cell lines were cultured at 37˚C in a 5% CO₂ humidified atmosphere. The logarithmic growth phase cells were collected for experiments. The blood samples obtained from 20 ENKL patients were collected at diagnosis prior to therapy and samples from six of the 20 patients were collected at efficacy evaluation (one, two and three cycles) during the chemotherapy. All patients provided written informed consent. The blood samples of 10 healthy volunteers (HVs) were provided by the Blood Bank of Henan Province (Zhengzhou, China). The PBMCs were isolated by density-gradient centrifugation using Ficol-paque (Tianjin Biotechnology Development, Tianjin, China) and used immediately for flow cytometry (FCM) analysis. The study was approved by the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China).

Tissue samples. The specimens of 30 ENKL patients (21 males and nine females; mean age, 47 years; age range, 15-68 years) and 25 rhinitis patients (15 males and 10 females; mean age, 52 years; age range, 12-76 years) were obtained from the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) between 2010 and 2012. The lesions were all located in the nasal cavity and the pathological tissues were formalin-fixed and paraffin-embedded (FFPE). The diagnosis and classification were performed according to the 2008 WHO diagnosis and classification criteria (2). Clinical staging was conducted according to Ann Arbor stage [stage I (n=6), stage II (n=15), stage III (n=5) and stage IV (n=4)] (14). The specimens were selected according to the following criteria: Patients who had not received radiotherapy and chemotherapy; and availability of complete clinical and pathological data. The slices were reviewed by two senior pathologists.

Fluorescence-based quantitative polymerase chain reaction (qPCR). In total, 5x10⁶ cells in logarithmic growth phase were collected. The total RNA was extracted using a RNA extraction kit spin column method (Qiagen, Beijing, China) according to the manufacturer’s instructions. Finally, 60 µl RNA was collected and RNA purity (D260/D280) was 1.8-2.0, tested using an ultraviolet spectrophotometer [SMA4000; Merinton (Beijing) Instrument, Ltd., Beijing, China]. Subsequently, reverse transcription was conducted according to the RevertAid™ First Strand cDNA synthesis kit (Fermentas, Shenzhen, China) recommendations. In total, 20 µl cDNA was obtained and stored at -20˚C until use. The following primers (synthesized by Sangon, Shanghai, China) were used for cDNA amplification system: Forward, CAT CTT ATT ATG CCT TGT AGC A and reverse, GGA TTA CGT CTC CTC CAA ATG TG for PD-L1; forward, CAA CTT GGC TGC TTT ACA ACA TT and reverse, TGT GGT GAC AGG TTT TGT TGT GGT for PD-L2; and forward, TGA CGT GGA CAT CCG CAA AG and reverse, CTA GAA GGT GGA CAG GG for β-actin. The amplification products were 146, 110 and 205 bp, respectively.
was performed using the SYBR Green Mixture kit (CoWin Biotech Co., Ltd., Beijing, China) according to the manufacturer’s instructions. The data was normalized to the β-actin expression of NK cells and analyzed using the ABI 7500 Fast system (Applied Biosystems, Foster City, CA, USA). The qPCR was repeated three times.

**Immunohistochemistry (IHC).** The IHC streptavidin-peroxidase (SP) staining method was performed on 4 μm-thick FFPE tissue sections containing NKTL and rhinitis tissues. The sections were deparaffinized, dehydrated in xylene and graded ethanol solutions. The antigen retrieval was conducted in 0.01 mol/l citrate (pH 6.0) and the slides were incubated overnight with rabbit anti-human PD-L1 polyclonal antibody (1:120; Proteintech, Chicago, IL, USA), rabbit anti-human PD-L2 polyclonal antibody (1:150) and mouse anti-human PD-1 monoclonal antibody (mAb; 1:100) (both ZSGB-BIO, Beijing, China) and phosphate-buffered saline was used as a blank control. Incubation of the biotinylated secondary antibody with horseradish peroxidase (HRP) and 3,3-diaminobenzidine chromogen (all from ZSGB-BIO, Beijing, China) was performed sequentially. Next, the slides were counterstained with hematoxylin and then covered with neutral balsam. The PD-1, PD-L1 and PD-L2 protein expression in the rhinitis tissue served as controls.

**IHC scoring.** PD-L1, PD-L2 and PD-1 expression were evaluated as staining at the cell membrane and cytoplasm. Positive staining for PD-L1 and PD-L2 was determined by staining intensity and the percentage of positive cells was determined according to the methods used in tumors (12,13,15). The following staining intensity grading was used: 0, no staining; 1, faint yellow; 2, claybank; and 3, sepia. The percentage of the positive tumor cells was scored as follows: 1, <10%; 2, 10-50%; 3, >50%. The positive cases were then classified according to the product of the staining intensity and positive tumor cell values as follows: Positive, >3 points; and negative, <3 points. The mean count of PD-1 positive cells of the 30 cases was used as the threshold and the cases were divided into high PD-1 tumor-infiltrating T lymphocytes (TILs) and low PD-1+ TIL groups according to the threshold.

**Magnetic-activated cell sorting (MACS).** The PBMCs were isolated from the HFs using the previously described methods. The MACS was then conducted by a standard method. CD8+ T cells were separated using CD8 and CD56 microbeads (BD Biosciences, Heidelberg, Germany) for NKS. The purity of these cells was measured by FCM.

**FCM.** FCM was performed by a standard method and the results were acquired using a FACSCanto II cytometer (BD Biosciences) and analyzed using BD CellQuest Pro software (BD Biosciences). The following antibodies were used to measure the expression of PD-1 in the PBMCs: Mouse monoclonal anti-human-CD3-peridinin (Percp) (Catalogue number: 347344, clone: SK7), monoclonal mouse anti-human-CD8-fluorescein isothiocyanate (FITC) (cat. no.: 340962, clone: SK3), monoclonal mouse anti-human-CD8-allophycocyanin-cyanine 7 (Cy7) (cat. no.: 557760, clone: RPA-T8) and monoclonal mouse anti-human-PD-1-phycocerythrin (PE)-Cy7 (cat. no.: 561272, clone: EH12.1). The mAb was used to measure the purity of CD8+ T and NK cells separated by MACS, including monoclonal mouse anti-human-CD8-Percp (cat. no.: 341004, clone: SK7), monoclonal mouse anti-human-CD3-PE-Cy7 (cat. no.: 557749, clone: SP34-2) and monoclonal mouse anti-human-CD56-FITC (cat. no.: 340410, clone: NCAM162.2). The mouse IgG-PITC isotype control antibodies were also used. The antibodies used in FCM were all purchased from BD Pharmingen (San Diego, CA, USA).

**Enzyme-linked immunosorbent assays (ELISA).** T-helper type 1 (Th1) cytokines (IL-2 and IFN-γ) that had secreted into the serum of the 20 ENKL patients and 10 HVs were detected by Quantikine HS ELISA kits (R&D Systems, Minneapolis, MN, USA). Blood samples were collected and, following centrifugation of the blood samples at 1,100 x g for 10 min, the serum was obtained. The standard and blank wells were placed separately in the coated ELISA plates and the test samples were diluted with sample diluent (R&D Systems) and added to the test sample wells. Following the addition of the HRP-conjugate reagent (with the exception of the blank well), the samples were incubated at 37°C in a humidified atmosphere of 5% CO2 for 72 h and washed five times with scrubbing solution (R&D Systems) subsequently the chromogen solutions A and B were added. Following five times washing of the wells with scrubbing solution, the stop solution was added to terminate the reaction. The blank well was taken as zero and the absorbance optical density values were read at 450 nm within 15 min. The concentrations of IL-2 and IFN-γ were determined by standard curves. All experiments were repeated three times.

**Functional experiments.** To delineate the role of the PD-Ls in tumor T-cell interactions in ENKL, coculture experiments were performed by simulating the tumor microenvironment in vivo. The experiments were divided into the following groups: i) SNK-6/CD8+ T-cell control group; ii) SNK-6 and activated CD8+ T-cell group; and iii) SNK-6, activated CD8+ T-cell and anti-PD-L1 antibody group. The purified allogeneic CD8+ T cells were then plated in 24-well plates at a density of 6x10⁶ cells/well, and activated with phytohemagglutinin (PHA; 2 μg/ml, Sigma-Aldrich, St. Louis, MO, USA) for 48 h. Next, the allogeneic CD8+ T cells were cocultured with 6x10⁵ SNK-6 cells stained with 5 mmol/l carboxylfluorescein succinimidyld ester (CFSE; BD Pharmingen) in the presence of the anti-PD-L1 antibody (6 μg/ml; MIH1 clone; eBioscience, Inc., San Diego, CA, USA) or the mouse IgG1 isotype control mAbs. The ratio of effective and target cells was 10:1. For the measurement of the SNK-6 cell proliferation, the SNK-6 cells were used as the control group. The cells in each group were harvested at 0, 24, 48 and 72 h and analyzed by FCM gating CFSE+ events. Following the coculture of the SNK-6 and CD8+ T cells for 72 h, the supernatants were removed to measure the Th1 cytokine (IL-2 and IFN-γ) secretion by ELISA, of which the SNK-6 cells were used as the control group. CD8+ T-cell apoptosis was analyzed at 72 h by FCM gating Annexin V and 7-aminoactinomycin D (AAD) (Annexin-V-PE-A and 7-AAD-Percp-cy5-5-A; BD Pharmingen) cells, and the activated CD8+ T cells were simultaneously used as the control group.
Statistical analysis. SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. Data are presented as the mean ± standard deviation. Spearman’s rank correlation test was used to examine the correlation between PD-L1 and PD-L2 and the clinicopathological parameters. The χ² test was used to analyze the positive expression rate, and Student’s t-test and one-way analysis of variance were used to analyze the differences among the groups. For all comparisons, P<0.05 was considered to indicate a statistically significant difference.

Results

mRNA expression of PD-L1 and PD-L2 in NHL cell lines. The levels of PD-L mRNA in ENKL and other NHL cell lines were detected by qPCR. The expression of PD-L1 and PD-L2 in SNK-6 and YTS cells was significantly elevated compared with that in the normal NK cells (P<0.05; Fig. 1A). In addition, PD-L1 and PD-L2 were expressed in the T- and B-cell lymphoma cell lines. However, the expression of PD-L1 and PD-L2 mRNA in the T-cell lymphoma cell lines was higher than that in the B-cell lymphoma cell lines (Fig. 1A). The purity of NK cells separated by MACS was 97.8% (Fig. 1B). In addition, the expression of PD-1 was not detected in the ENKL cell lines, SNK-6 or YTS (data not shown).

Expression of PD-L1, PD-L2 and PD-1 proteins, and correlation between PD-L1 and PD-L2 and clinical pathological parameters of ENKL. PD-L1, PD-L2 and PD-1 proteins were
all located in the cytoplasm and cell membrane, and the expression of PD-L1 and PD-L2 was detected in tumor and stromal cells. However, PD-1 was predominantly expressed in the tumor stromal lymphocytes (Fig. 2). The positive expression of PD-L1 and PD-L2 in ENKL tumor cells was 60.0 and 63.3%, respectively, which was significantly increased compared with that in the rhinitis tissues (16.0 and 12%; \(P<0.05\)). The count of PD-1\(^+\) TILs in the 30 ENKL cases (range, 0 - 18; mean, 7.56) was significantly increased in contrast to that in the rhinitis tissues (range, 0 - 9; mean, 1.52) \(P<0.05\). The mean value of 7.56 was used as the threshold and, according to this, the 30 ENKL cases were divided into a PD-1\(^+\) TIL high-density group (16 cases) and low-density group (14 cases). The expression of PD-L1 and PD-L2 was found to inversely correlate with PD-1\(^+\) TILs. Furthermore, the expression of PD-L1 and PD-L2 was found to positively correlate with tumor stage. PD-L1 but not PD-L2 expression was also found to positively correlate with the international prognostic index (IPI) and lactate dehydrogenase (LDH) and Ki-67 levels. However, no correlation was identified between PD-L1 and PD-L2 expression and the other clinical histopathological parameters (Table I).

**Table I. Correlation between PD-L1 or PD-L2 protein expression in ENKL tissues and the clinicopathological parameters of the 30 ENKL patients.**

| Variables       | PD-L1, n |       |       | P-value |       |       |       | P-value |
|-----------------|----------|-------|-------|---------|-------|-------|-------|---------|
|                 | Total, n | -     | +     | +       | -     | +     |       | +       |
| Gender          |          |       |       |         |       |       |       |         |
| Male            | 21       | 10    | 11    |          | 8     | 13    | 0.193 | 8       |
| Female          | 9        | 2     | 7     |          | 3     | 6     | 0.804 |         |
| Age, years      |          |       |       |         |       |       |       |         |
| ≥45             | 17       | 7     | 10    |          | 6     | 11    | 0.880 |         |
| <45             | 13       | 5     | 8     |          | 5     | 8     | 0.858 |         |
| PS score        |          |       |       |         |       |       |       |         |
| ≤80             | 15       | 7     | 8     |          | 5     | 10    | 0.456 |         |
| >80             | 15       | 5     | 10    |          | 6     | 9     | 0.705 |         |
| IPI score       |          |       |       |         |       |       |       |         |
| ≤2              | 20       | 11    | 9     |          | 8     | 12    | 0.018 | 0.592   |
| >2              | 10       | 1     | 9     |          | 3     | 7     |       |         |
| Stage           |          |       |       |         |       |       |       |         |
| I+II            | 21       | 11    | 10    |          | 11    | 10    | 0.006 |         |
| III+IV          | 9        | 1     | 8     |          | 0     | 9     |       |         |
| LDH             |          |       |       |         |       |       |       |         |
| <281            | 23       | 12    | 11    |          | 10    | 13    | 0.014 | 0.161   |
| ≥281            | 7        | 0     | 7     |          | 1     | 6     |       |         |
| β2-MG           |          |       |       |         |       |       |       |         |
| <3              | 20       | 9     | 11    |          | 7     | 13    | 0.429 | 0.789   |
| ≥3              | 10       | 3     | 7     |          | 4     | 6     |       |         |
| EBER            |          |       |       |         |       |       |       |         |
| Positive        | 25       | 9     | 16    |          | 8     | 17    | 0.317 | 0.236   |
| Negative        | 5        | 3     | 2     |          | 3     | 2     |       |         |
| Ki-67, %        |          |       |       |         |       |       |       |         |
| <60             | 15       | 9     | 6     |          | 5     | 10    | 0.025 | 0.705   |
| ≥60             | 15       | 3     | 12    |          | 6     | 9     |       |         |

PD-L, programmed death ligand; ENKL, extranodal natural killer/T-cell lymphoma, nasal type; PS, performance status; IPI, international prognostic index; LDH, lactate dehydrogenase; β2-MG, β2-microglobulin; EBER, Epstein-Barr virus-encoded small RNA.
The mean production levels of IL-2 and IFN-γ in the serum of 20 ENKL patients were significantly lower than that of the 10 HVs (Fig. 3F; P<0.05).

Functional significance of PD-L1 expression for purified allogeneic CD8+ T-cell interactions. As PD-1 expression was elevated in the TILs of the ENKL tissues, and PD-L1 and PD-L2 expression was elevated in the tumor cells and cell lines, coculture experiments of the SNK-6 cells and purified allogeneic CD8+ T cells (effector:target ratio, 10:1) were established by simulating the tumor microenvironment in vivo. The purity of CD8+ T cells separated by MACS was 99% (Fig. 4A). In the functional studies, PD-1 expression was characterized in the allogeneic CD8+ T cells stimulated with PHA for 48 h, and the percentage of CD8+ PD-1+ T cells was 96.2% (Fig. 4B). A significant inhibitory effect of PD-L1 was identified for cytokine secretion (IL-2 and IFN-γ) in the allogeneic CD8+ T-cell subset, and this inhibitory effect was restored with the PD-L1 blocking antibody (P<0.05; Fig. 4C). The CD8+ T-cell apoptosis in groups A and B was not altered.
significantly compared with that of activated CD8<sup>+</sup> T cells at 72 h (P>0.05; Fig. 4D). The SNK-6 cell proliferation was detected using CD8<sup>+</sup>T-cell cytotoxic activity, and the proliferation index was not altered significantly (P>0.05; Fig. 4E).

**Discussion**

ENKL is characterized by a highly aggressive clinical course, poor prognosis and is analogous to ANKL (16). Generally,
ENKL patients have immunosuppression or immune disorders and, therefore, we suspect that the expression of immune inhibitory molecules in ENKL tumor cells impedes or paralyzes the antitumoral immune responses. It was indicated that using tumor antigen-specific CTLs against tumor cells is likely to have broad application prospects in the treatment of malignancies. However, the functional activity of tumor-specific T cells is likely to be attenuated by its receptor (CTLA-4 and PD-1) interactions with its ligands, which transfer negative regulation signals and ultimately prevent an effective antitumor immune response (10). Thus, the manner in which to improve tumor cell immunogenicity or interfere with the biological signal for immune evasion is likely to be via hotspots in ENKL immunotherapy studies.

The B7 immunoglobulin superfamily are the sole costimulatory molecules which deliver regulatory signals from the antigen-presenting cells (APCs) to the T cells. At present, the B7 family comprises eight members: CD80 (B7-1), CD86 (B7-2), CD274 (PD-L1 or B7-H1), CD273 (PD-L2 or B7-DC), CD275 (B7-H2 or ICOS-L), CD276 (B7-H3), B7-H4 (B7S1 or B7x) and B7-H6 (17). PD-L1 is predominantly expressed in activated T and B cells, APCs, (dendritic cells) DCs, macrophages and human tumor cells (16). PD-L2 is not only expressed in DCs and macrophages, but also in immunocytes, including Th2. The gene structure, gene sequence and function of PD-L2 are similar to that of PD-L1 (18), and the extracellular region of PD-L1 is 28% identical to that of CTLA-4 (19). In addition, PD-L1 is expressed in activated T and B lymphocytes, myeloid cells and thymocytes (16).

PD-L1 and PD-L2, but particularly PD-L1, are extensively expressed in entity tumors and hematopoietic malignancies (9). Although PD-L1 and PD-L2 molecules share 34% identity of amino acids, their expression has been suggested to be differentially regulated (20). Furthermore, PD-L1 exhibits a more extensive expression pattern and higher expression intensity than PD-L2 in Hodgkin’s lymphoma (HL) and NHL (21-23). However, the expression of PD-1, PD-L1 and PD-L2 in ENKL has never been shown. The current study detected the expression and distribution of PD-1, PD-L1 and PD-L2 in ENKL. The results showed that PD-L1 and PD-L2 are aberrantly expressed at a high level in the cell lines compared with normal NK cells. In addition, PD-L1 and PD-L2 were found to simultaneously exhibit higher expression levels in T-cell lymphoma than B-cell lymphoma. By contrast, the ENKL cell lines, SNK-6 and YTS, were found to lack expression of PD-1. In the IHC analysis, the PD-L1 and PD-L2 proteins were found to be located in the cytoplasm and cell membrane of tumor and stromal cells. However, PD-1 was predominantly expressed in tumor stromal lymphocytes. PD-L1 and PD-L2 expression in ENKL tumor cells was significantly increased in contrast to that in the rhinitis tissues. In human pancreatic cancer, tumor PD-L1 but not PD-L2 expression showed a poorer postoperative prognosis and PD-L1 expression was found to inversely correlate with tumor antigen-specific CD8+ T cells (24). In human esophageal cancer, no correlation was identified between PD-L1 expression and TILs (25). However, no correlation was identified between PD-1 and PD-L1 expression and the stage of disease or LDH in chronic lymphocytic leukemia (26). The results of the current study found that PD-L1 and PD-L2 expression in tumor cells positively correlates with clinical stage. In addition, PD-L1 but not PD-L2 expression was found to positively correlate with LDH and Ki-67 levels, as well as negatively correlate with IPI score. However, no significant correlation was identified between PD-L1 and PD-L2 expression, and the other clinical histopathological parameters. Notably, Greene et al (27) using EBV-transformed B cells demonstrated that the EBV-encoded latent membrane protein 1 through activator protein 1 and JAK-STAT signaling can upregulate PD-L1 expression. The aberrant signaling through EBV-encoded gene products provides alternative mechanisms to promote PD-L1 expression in EBV-positive classical Hodgkin lymphoma and post-transplant lymphoproliferative disorders (13). However, the results of the current study showed no correlation between EBV-encoded small RNA and PD-L1 and PD-L2 expression in ENKL. However, the reason for this may be due to the limited number of cases. In the present study, PD-L1 and PD-L2 expression were found to negatively correlate with PD-1+ TILs. The results of the current study markedly indicated that ENKL tumor cells inhibit TIL activity or promote TIL apoptosis, ultimately promoting immune evasion via the PD-1/PD-L pathway. The Th1 cytokine (IL-2 and IFN-γ) levels were also detected in the serum and found to be significantly decreased. In addition, the immune inhibitory receptor PD-1 expression in CD4+ and CD8+ T cells was significantly upregulated in the 20 ENKL patients in contrast to that in the 10 HVs. These observations not only indicated that the immune function in ENKL patients is suppressed, but were also in favor of the theory that cellular immunity deficiency frequently occurs in cancer patients. PD-1 has been identified as a prognostic risk factor in follicular lymphoma and a marker of angioimmunoblastic T-cell lymphoma (28,29). However, the current study found that PD-1 expression levels are attenuated with chemotherapy. This phenomenon may be explained by the robust increase in the PD-1 expression of T lymphocytes in ENKL patients when the cells are activated by specific antigens. In addition, we suspect that chemotherapy may alter the tumor antigen-specific response.

PD-L1 has been proposed as a bridge to connect the innate and adaptive immunity in combating leukemia (30). In ovarian cancer, the lysis of tumor cells with PD-L1 overexpression in CTLs is attenuated, however, when PD-L1 is silenced, the lysis is promoted. In mouse models of ovarian cancer following peritoneal dissemination, PD-L1 depletion has been found to inhibit tumor growth and prolong survival (31). Andorsky et al (21) established a coculture system of ALCCL cell lines and allogeneic T cells, and it was observed that T-cell proliferation and IFN-γ secretion was increased in the presence of the anti-PD-L1 blocking antibody. In conclusion, the activity of CTL was inhibited by tumor cells via the PD-L1/PD-1 negative regulation pathway. However, antitumor immune response was restored using a recombinant soluble PD-L1 or blocking antibodies to interfere with the PD-L1/PD-1 pathway in specific types of tumors. The current study simulated the in vivo tumor environment and CD8+ T cells were activated as effective cells by incubation with PHA for 48 h, and PD-1 expression was significantly elevated compared with the unactivated CD8+ T cells. Subsequently, SNK-6 cells and purified activated CD8+ T cells were cocultured for 72 h in the presence or absence of the PD-L1 blocking antibody. Consequently, no significant change in CD8+ T cell apoptosis and SNK-6 proliferation with or without PD-L1 blocking antibody was identified. However, a significant inhibitory effect of PD-L1 for allogeneic CD8+
T-cytokine secretion (IL-2 and IFN-γ) was identified and this inhibitory effect was restored with the PD-L1 blocking antibody. The results of the current study showed that PD-L1 expression in SNK-6 cells inhibits the Th1 cytokine secretion of CD8+ T cells in vivo. Although PD-L1 is frequently expressed in malignant cells, the regulatory mechanisms are not uniform and a number of complex signaling pathways are involved in its regulation in HL and NHL (with the exception of ENKL), such as MEK/ERK, NF-jB, PI3K/Akt, JAK/STAT and p38 MAPK (32,33). Furthermore, two major regulatory pathways of PD-1/PD-L2 are the NFkB and STAT6 pathways (18). However, the regulatory mechanisms of PD-1/PD-L in ENKL are less well known; therefore, future studies are required to delineate the role of PD-L interaction with tumor T cells in vivo.

Currently, bioimmunotherapy is a pivotal study field in the therapy of tumors. However, the immunotherapy of ENKL remains immature. The results of the current study revealed that PD-Ls and PD-1 are aberrantly expressed in ENKL and may prevent effective antitumor immunity in vivo by interacting with tumor T cells, which provides important information to reveal the cellular immune deficiency mechanism in ENKL. Future studies in animal models and patients are required to fully delineate the immune regulation functions of PD-Ls as well as molecules involved in the mediation mechanism of ENKL. Thus, the manner in which to selectively block these inhibitory molecules is likely to present an attractive approach to ENKL immunotherapy.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81172118). The authors would like to thank the Institute of Clinical Medicine, the Biotherapy Center and the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) for their assistance.

References

1. Harabuchi Y, Takahara M, Kishibe K, et al: Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features. Int J Clin Oncol 14: 181-190, 2009.
2. Jaffe ES: The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematol Am Soc Hematol Educ Program 2009: 523-531, 2009.
3. Mao Y, Zhang DW, Zhu H, et al: LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTCL). Diag Pathol 7: 178, 2012.
4. Roma E and Smith AG: Epidemiology of lymphoma. Histopathology 58: 4-14, 2011.
5. Suzuki R: NK/T-Cell Lymphomas: pathobiology, prognosis and treatment paradigm. Curr Oncol Rep 14: 395-402, 2012.
6. Chen L: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4: 336-347, 2004.
7. Fife BT, Panken KE, Eagar TN, et al: Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 10: 1185-1192, 2009.
8. Atanackovic D, Luetkens T and Kröger N: Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia: Oct 23, 2013 (Epub ahead of print).
9. Zitvogel L and Kroemer G: Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1: 1223-1225, 2012.
10. Iwamura K, Kato T, Miyahara Y, et al: siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. Gene Ther 19: 959-966, 2012.
11. Brahem JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465, 2012.
12. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454, 2012.
13. Chen BJ, Chapuy B, Ouyang J, et al: PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 19: 3462-3473, 2013.
14. Beahrs OH, Henson DE and Hutter RVP (eds): Handbook for staging of cancer, from the manual for staging of cancer. 4th ed. American joint committee on cancer (AJCC) JB Lippincott Co, 257 1992.
15. Taube JM, Anders RA, Young GD, et al: Colocalization of inflammatory response with B7-h1 expression in human melanoctyic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4: 127ra37, 2012.
16. Li Y, Wang J, Li C and Ke XY: Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk Lymph 55: 2015-2023, 2012.
17. Greaves F and Gribben JG: The role of B7 family molecules in hematological malignancy. Blood 121: 734-744, 2013.
18. Rozali EN, Hato SV, Robinson BW, et al: Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012: 656340, 2012.
19. Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11: 3887-3895, 1992.
20. Loke P and Allison JP: PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 100: 5336-5341, 2003.
21. Ljungmblad DJ, Yamada RE, Said J, et al: Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 17: 4232-4244, 2011.
22. Yamamoto R, Nishikori M, Kitawaki T, et al: PD-L1/PD-L1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111: 3230-3242, 2008.
23. Brusa D, Serra S, Coscia M, et al: The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 98: 953-963, 2013.
24. Nomi T, Shu M, Akahori T, et al: Clinical significance and therapeutic potential of the programmed death-ligand programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13: 2151-2157, 2007.
25. Ohigashi Y, Shu M, Yamada Y, et al: Clinical significance of programmed death-ligand 1- and programmed death-ligand 2 expression in human esophageal cancer. Clin Cancer Res 11: 2947-2953, 2005.
26. Grzywnowicz M, Zaleska J, Mertens D, et al: Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PLoS One 7: e35178, 2012.
27. Green MR, Rodig S, Juszczynski P, et al: Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18: 1611-1618, 2012.
28. Takahashi H, Tomita N, Sakata S, et al: Prognostic significance of programmed cell death-ligand-1-positive cells in follicular lymphoma patients may alter in the rituximab era. Eur J Haematol 90: 286-290, 2013.
29. Ohmatsu H, Suqaya M, Fujita H, et al: Primary cutaneous follicular helper T-cell lymphoma treated with allogeneic bone marrow transplantation: immunohistochemical comparison with angioimmunoblastic T-cell lymphoma. Acta Derm Venereol: Jan, 2014 (Epub ahead of print).
30. Chen L: B7-H1 expression and therapeutic potential of the programmed death-ligand programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 17: 4232-4244, 2011.
31. Ohigashi Y, Shu M, Yamada Y, et al: Clinical significance of programmed death-ligand 1- and programmed death-ligand 2 expression in human esophageal cancer. Clin Cancer Res 11: 2947-2953, 2005.